Novartis Expects to Sustain Long-Term Growth With Pipeline of Potential Blockbuster Drugs
December 05 2019 - 2:08AM
Dow Jones News
By Giulia Petroni
Novartis AG (NOVN.EB) said Thursday that it expects to sustain
long-term growth with a pipeline of more than 25 potential
blockbuster drugs.
"The near term brings yet another catalyst-rich period with
pipeline progress across the portfolio that can sustain long-term
growth," said Chief Executive Vas Narasimhan.
The Swiss drug giant said it counts 60 projects in Phase 2
pipeline with more than 10 advancing into Phase 3 or pivotal trials
each year in the 2020-21 period. Over 90% are projected to be
"first-in-class or first-in-indication," it said.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
December 05, 2019 01:53 ET (06:53 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
